Jointly provided by Dannemiller and Pharmacy Times Office of Continuing Professional Education.
Optimizing Management of Allergic Rhinitis in Convenient Care Clinics
Kristen L. Marjama, DNP, FNP-BC
Education and Training Manager
Walmart Care Clinics
Fort Lauderdale, Florida
Yvette C. Terrie, BSPharm, RPh
At the completion of this activity, the participant will be able to:
Statement of Need
Review the prevalence, pathophysiology, and consequences of allergic rhinitis (AR)
Recall which pharmaceutical agents should be selected for the management of AR based on specific patient and drug characteristics
Discuss the role of subcutaneous and sublingual immunotherapy in select patients with AR
Allergic rhinitis (AR) is a chronic, inflammatory condition of the upper respiratory tract, particularly the nasal mucosa, that quickly becomes a significant socioeconomic burden and can cause problems with a patient’s quality of life. With an estimated 50 million Americans and 400 million individuals affected worldwide, AR is one of the most common diseases that affects adults and is the most common disease affecting children. In terms of cost, AR costs $2 to $5 billion in direct health expenditures each year. It is not considered a life-threatening or serious disease, but the underlying complications and risk factors for other more serious conditions cause an overarching effect on quality of life, productivity, and asthma control. Therefore, it is important to examine prevalence, pathophysiology, and consequences of AR, as well as the pharmaceutical agents based on patient-related factors and drug-specific characteristics that are available to help patients manage their AR.
This activity is intended for advanced practice nurses, including nurse practitioners and physician assistants, working in convenient care clinics.
October 7, 2015
October 7, 2016
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Dannemiller and Pharmacy Times. Dannemiller is accredited by the ACCME to provide continuing medical education for physicians.
Dannemiller designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™
from organizations accredited by ACCME.
Dannemiller is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners: AANP Provider Number 090419.
This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standards. It provides 1.0 contact hour(s) of continuing education, which includes 0.5 hour(s) of pharmacology.
Method of Participation
To receive credit, all participants will need to read the objectives and other introductory CME/CE information, take the pretest and then proceed to the educational activity. Once the activity is completed along with the posttest and the evaluation, participants can request credit.
You will have access to your certificate immediately following completion of the evaluation. Credit is provided through 10/7/2016. No credit will be given after this date. There is no fee to participate in this activity.
In the event you have questions about this activity or are unable to retrieve the certificate, please e-mail firstname.lastname@example.org and a certificate will be emailed within 2 weeks.
System Requirements for Completion of Post-Test and Evaluation
Computer or smart phone with internet access
Kristen L. Marjama, DNP, FNP-BC
In accordance with the Accreditation Council for Continuing Medical Education (ACCME), Dannemiller requires that any person who is in a position to control the content of a CME/CE activity must disclose all financial relationships they have with a commercial interest.
The following individuals, who are associated with the planning and execution of this activity, have stated they have no financial relationships with commercial interests: Dave Heckard (Pharmacy Times), Maryjo Dixon (Pharmacy Times), Yvette Terrie (Pharmacy Times), Jim Palatine (Pharmacy Times), Erin Fletcher (Dannemiller), Kristen L. Marjama (Faculty).
Off label statement provided: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Dannemiller or Pharmacy Times Office of Continuing Professional Education. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject